KBC Group NV Has $2.20 Million Position in Zimmer Biomet Holdings, Inc. (ZBH)

KBC Group NV reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 31.2% during the first quarter, Holdings Channel reports. The fund owned 18,010 shares of the medical equipment provider’s stock after selling 8,168 shares during the period. KBC Group NV’s holdings in Zimmer Biomet Holdings were worth $2,199,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZBH. Norges Bank acquired a new stake in Zimmer Biomet Holdings during the fourth quarter worth approximately $234,271,000. Thrivent Financial for Lutherans boosted its stake in Zimmer Biomet Holdings by 6.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 7,144 shares of the medical equipment provider’s stock worth $737,000 after buying an additional 450 shares during the period. Federated Investors Inc. PA boosted its stake in Zimmer Biomet Holdings by 256.6% in the fourth quarter. Federated Investors Inc. PA now owns 394,585 shares of the medical equipment provider’s stock worth $40,721,000 after buying an additional 283,935 shares during the period. Levin Capital Strategies L.P. boosted its stake in Zimmer Biomet Holdings by 41.9% in the fourth quarter. Levin Capital Strategies L.P. now owns 556,036 shares of the medical equipment provider’s stock worth $57,383,000 after buying an additional 164,132 shares during the period. Finally, GLG LLC boosted its stake in Zimmer Biomet Holdings by 6.8% in the fourth quarter. GLG LLC now owns 10,058 shares of the medical equipment provider’s stock worth $1,038,000 after buying an additional 639 shares during the period. 84.63% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at 125.92 on Friday. The firm has a market cap of $25.39 billion, a price-to-earnings ratio of 51.54 and a beta of 1.23. Zimmer Biomet Holdings, Inc. has a 1-year low of $95.63 and a 1-year high of $133.21. The firm’s 50-day moving average price is $120.97 and its 200-day moving average price is $116.09.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings results on Thursday, April 27th. The medical equipment provider reported $2.13 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.02. The company had revenue of $1.98 billion during the quarter, compared to the consensus estimate of $1.96 billion. Zimmer Biomet Holdings had a return on equity of 16.80% and a net margin of 6.36%. Zimmer Biomet Holdings’s revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.00 earnings per share. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.54 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, July 28th. Shareholders of record on Friday, June 23rd will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.76%. The ex-dividend date is Wednesday, June 21st. Zimmer Biomet Holdings’s payout ratio is 39.67%.

ILLEGAL ACTIVITY WARNING: “KBC Group NV Has $2.20 Million Position in Zimmer Biomet Holdings, Inc. (ZBH)” was published by WKRB News and is the sole property of of WKRB News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.wkrb13.com/markets/2230036/kbc-group-nv-has-2-20-million-position-in-zimmer-biomet-holdings-inc-zbh.html.

A number of analysts have recently commented on the company. Needham & Company LLC boosted their price objective on Zimmer Biomet Holdings from $151.00 to $153.00 and gave the company a “strong-buy” rating in a research report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $132.00 price objective on Zimmer Biomet Holdings and gave the company a “buy” rating in a research report on Friday, April 28th. ValuEngine cut Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Royal Bank Of Canada restated a “buy” rating and issued a $133.00 price objective on shares of Zimmer Biomet Holdings in a research report on Tuesday, March 14th. Finally, Citigroup Inc. boosted their price objective on Zimmer Biomet Holdings from $108.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, June 9th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $135.88.

In other Zimmer Biomet Holdings news, insider Sang Yi sold 17,731 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $124.56, for a total transaction of $2,208,573.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David C. Dvorak sold 87,331 shares of the firm’s stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $116.47, for a total value of $10,171,441.57. Following the transaction, the insider now directly owns 381,886 shares of the company’s stock, valued at approximately $44,478,262.42. The disclosure for this sale can be found here. Insiders have sold 112,302 shares of company stock valued at $13,230,422 in the last three months. 1.07% of the stock is currently owned by company insiders.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230036/kbc-group-nv-has-2-20-million-position-in-zimmer-biomet-holdings-inc-zbh.html

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.